Director D. Gary Gilliland to resign from Nuvalent Board, join scientific advisory board

Nuvalent, Inc.

Dr. Gilliland notified Nuvalent of resignation effective at 2025 annual meeting.
Will enter consulting agreement to serve on scientific advisory board post-resignation.
Resignation not due to any disagreement on operations, policies, or practices.
Dr. Gilliland currently serves on Board and all committees; departure is planned transition.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

D. Gary Gilliland

member of the board of directors

NUVL · Nuvalent, Inc.

Filed: April 17, 2025, 7:59 PM ET

On April 11, 2025, D. Gary Gilliland, M.D., Ph.D., a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of his decision to resign from the Board and from all committees of the Board on which he serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

D. Gary Gilliland resigned as member of the board of directors at Nuvalent, Inc..

Action: resigned
Role: member of the board of directors

Exact text from the filing

On April 11, 2025, D. Gary Gilliland, M.D., Ph.D., a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of his decision to resign from the Board and from all committees of the Board on which he serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders.

View on SEC.gov

Nuvalent, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-055491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.